Table I.
Baseline clinical characteristics of patients.
| Characteristic | Control group (n=15) | Immunotherapy group (n=14) | P-value |
|---|---|---|---|
| Gender (male/female) | 14/1 | 14/0 | 0.368 |
| Age (years, mean ± SD) | 54.0±7.5 | 51.5±9.3 | 0.154 |
| Maximum diameter of tumor (mm, mean ± SD) | 25.14±7.87 | 23.79±7.30 | 0.845 |
| Hepatitis B/C | 14/1 | 14/0 | 0.368 |
| Child-Pugh classification (A/B) | 15/0 | 13/1 | 0.261 |
| Pathology (Well/moderately/poorly-differentiated) | 5/6/4 | 5/7/2 | 0.236 |
| ALT (µ/l) | 41.3±7.8 | 42.8±7.5 | 0.598 |
| AST (µ/l) | 46.1±7.2 | 46.4±7.9 | 0.252 |
| Follow-up time (months) | 16 | 19 | 0.663 |
SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase.